OmniAb, Inc.

Equities

OABI

US68218J1034

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
4.43 USD -2.85% Intraday chart for OmniAb, Inc. -3.49% -28.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
OmniAb Insider Bought Shares Worth $1,167,750, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Gain Pre-Bell Thursday MT
OmniAb Swings to Q4 Loss, Revenue Declines MT
Earnings Flash (OABI) OMNIAB Posts Q4 Revenue $4.8M, vs. Street Est of $7.46M MT
Transcript : OmniAb, Inc., Q4 2023 Earnings Call, Mar 20, 2024
OmniAb, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
OmniAb, Inc.(NasdaqGM:OABI) added to NASDAQ Biotechnology Index CI
OmniAb, Inc. Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference CI
Omniab Insider Bought Shares Worth $1,010,000, According to a Recent SEC Filing MT
RBC Initiates OmniAb at Outperform With $6 Price Target, Says Stock Gives Exposure to Growth Potential of Monoclonal Antibody Therapies MT
Omniab Insider Bought Shares Worth $405,517, According to a Recent SEC Filing MT
Transcript : OmniAb, Inc. - Special Call
OmniAb, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (OABI) OMNIAB Posts Q3 Revenue $5.5M, vs. Street Est of $10.3M MT
Omniab, Inc. Appoints Steve Love to Its Board of Directors and as Audit Committee Chair, Member of the Human Capital Management and Compensation Committee CI
A Collaborative Scientific Team Led by Researchers At the Applied Biomedical Science Institute, Scripps Research, Kansas State University, University of Louisville, Omniab, Inc., and Ligand Pharmaceuticals Discovers and Validates Potential New Class of Therapeutic Agent Based on the Unique Antigen Binding Regions of Cow Antibodies CI
Insider Buy: Omniab MT
OmniAb, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : OmniAb, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (OABI) OMNIAB Posts Q2 Revenue $6.9M, vs. Street Est of $11.9M MT
Omniab Announces the Passing of Director Sunil Patel CI
Hillstream Expands Collaboration With Minotaur, License Deal With OmniAb to Develop Cancer Treatments; Shares Rise MT
OmniAb, Inc.(NasdaqGM:OABI) added to Russell 3000E Index CI
OmniAb, Inc.(NasdaqGM:OABI) added to Russell Microcap Index CI
OmniAb, Inc.(NasdaqGM:OABI) dropped from Russell 2500 Growth Index CI
Chart OmniAb, Inc.
More charts
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.43 USD
Average target price
10 USD
Spread / Average Target
+125.73%
Consensus